The Leading Concerns of American Women with Nausea and Vomiting of Pregnancy Calling Motherisk NVP Helpline
Svetlana Madjunkova, Caroline Maltepe, Gideon Koren, Svetlana Madjunkova, Caroline Maltepe, Gideon Koren
Abstract
Background. Nausea and vomiting of pregnancy (NVP) is the most common medical condition of pregnancy, affecting up to 85% of expecting mothers. In the USA, there is no FDA-approved medication for the treatment of NVP. Objective. To identify the primary concerns of American women leading them to contact the Motherisk NVP Helpline and to characterize the severity of their symptoms and therapy offered in order to develop improved and customized counseling for them. Methods. We reviewed the intake forms of the American women who called the NVP Helpline from 2008 to 2012. We extracted their state of residence, demographic data, severity of NVP symptoms, and other available clinical characteristics. Results. A total of 195 forms were reviewed. Of these, 86% called for information on management of NVP with/without questions about fetal drug safety, while 14% called solely about drug safety during pregnancy/breastfeeding. The majority of women were Caucasian, in their thirties, educated, employed, married and in their second pregnancy. Of them 95% were suffering from moderate-to-severe condition with 13% having hyperemesis gravidarum. Conclusion. American women need more information on the management of NVP and on a variety of its aspects in addition to the safety and effectiveness of antiemetic medications. Their leading concern was the use of doxylamine and vitamin B6 combination for NVP treatment followed by the use of ondansetron.
Figures
References
- Koren G, Maltepe C, Gow R. Therapeutic choices for nausea and vomiting of pregnancy: a critical review of a systematic review. Journal of Obstetrics and Gynaecology Canada. 2011;33(7):733–735.
- Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of bendectin. Canadian Journal of Public Health. 1995;86(1):66–70.
- Einarson A, Maltepe C, Boskovic R, Koren G. Treatment of nausea and vomiting in pregnancy: an updated algorithm. Canadian Family Physician. 2007;53(12):2109–2111.
- Mazzotta P, Magee LA, Maltepe C, Lifshitz A, Navioz Y, Koren G. The perception of teratogenic risk by women with nausea and vomiting of pregnancy. Reproductive Toxicology. 1999;13(4):313–319.
- Ebrahimi N, Maltepe C, Bournissen FG, Koren G. Nausea and vomiting of pregnancy: using the 24-hour Pregnancy-Unique Quantification of Emesis (PUQE-24) scale. Journal of Obstetrics and Gynaecology Canada. 2009;31(9):803–807.
- Shrim A, Boskovic R, Maltepe C, Navios Y, Garcia-Bournissen F, Koren G. Pregnancy outcome following use of large doses of vitamin B6 in the first trimester. Journal of Obstetrics and Gynaecology. 2006;26(8):749–751.
- Maltepe C, Gow R, Koren G. Updated guidelines for the management of nausea and vomiting of pregnancy and hyperemesis gravidarum. In: Mattison DR, editor. Clinical Pharmacology During Pregnancy. 1st edition. Waltham, Mass, USA: Elsevier; 2013. pp. 157–171.
- Anderka M, Mitchell AA, Louik C, et al. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Research A: Clinical and Molecular Teratology. 2012;94(1):22–30.
- .
- Hale T. Doxylamine. Medications and Mothers’ Milk. A Manual of Lactation Pharmacology. Amarilo, Tex, USA: Hale Publishing; 2012.
- Hale T. Pyridoxine. Medications and Mothers’ Milk. A Manual of Lactation Pharmacology. Amarilo, Tex, USA: Hale Publishing; 2012.
- Koren G. Motherisk update. Is ondansetron safe for use during pregnancy? Canadian Family Physician. 2012;58(10):1092–1093.
Source: PubMed